Kornimate/medical-research-clean huggingface dataset:
blood biomarkers in major depression

Conditions: Major Depressive Disorder

Summary: depression is a leading cause of disability worldwide, affecting nearly 16% of the general population. its physiopathology remains unclear. based on gene-environment studies and epigenetic studies, a main hypothesis proposed that the major depressive episode (mde) results from the convergence of multiple factors including biological factors such as multi-genic vulnerability, hormonal and immunological variations as well as environmental factors. as a consequence, mrna could define a biological signature of the mde.


Eligibility criteria:
inclusion criteria: * major depressive disorder at inclusion according to the dsm iv at the time of the inclusion, * having a score on the scale of depression of hamilton ( hdrs-17) \> 19 at the time of the inclusion, * taken care by a grown-up psychiatric department, that the coverage(care) is realized in ambulatory or during a hospitalization exclusion criteria: * schizophrenia

Keywords: major depression
social & contextual impact on children undergoing liver transplantation

Conditions: Liver Transplantation; Liver Diseases

Summary: the social determinants of health have a large impact on health. for example, neighborhood socioeconomic deprivation is associated with increased risk of medication non-adherence, graft failure, and death in children after liver transplant. in order to address these socioeconomic inequities in outcomes, a more granular understanding of how the social determinants of health impact outcomes is needed. in this observational prospective cohort, caregivers of children undergoing liver transplantation will complete surveys and undergo in-depth, qualitative interviews. the survey will assess comprehensively for the social determinants of health (e.g. material economic hardship, health literacy, social connectedness, primary care quality, etc). the qualitative interviews will identify barriers and facilitators that socioeconomically deprived children/families have to obtaining the ideal outcome and identify health system opportunities to integrate social needs and medical care. data will be linked to an existing prospective cohort study (the society for pediatric liver transplant registry) to assess the impact of social risk on outcomes after transplant. healthcare providers who take care of children undergoing liver transplant will also be included in the qualitative interviews. the goal of including this group in the study is to determine the health systems barriers and facilitators to social needs screening and intervention.


Eligibility criteria:
inclusion criteria: caregivers/parents of children with the following criteria will be approached for inclusion in this study: * children \<18 years of age at the time of transplant * undergoing liver transplantation * guardian's consent, child assent (in accordance with each institution's irb policies) * consents to enrollment in split exclusion criteria: caregivers/parents of children undergoing liver transplantation will be excluded it: * caregiver unwilling or unable to complete the survey * child is a ward of the state (e.g., foster care) since present circumstances may not be reflective of child's past or future circumstances * non-english, non-spanish speakers * non-us residents * declined participation in split inclusion criteria for interview portion of the study: * participants who have completed the questionnaire or * medical team member involved in the care of children undergoing liver transplant (e.g., physician, nurse, social worker)

Keywords: pediatric health services research social determinants of health
post marketing surveillance for general drug use to assess the safety and efficacy profile of viviant in usual practice

Conditions: Osteoporosis

Summary: this survey is conducted for preparing application material for re examination under the pharmaceutical affairs laws and its enforcement regulation, and assessing the safety and efficacy profiles of viviant in usual practice according to the re-examination regulation for new drugs

continuous enrollment

Eligibility criteria:
inclusion criteria: * postmenopausal osteoporosis and osteopenia patients exclusion criteria: * patients with active or past history of venous thromboembolic events including deep vein thrombosis, * patients with pulmonary embolism and retinal vein thrombosis

Keywords: osteoporosis postmenopausal serm
prf for accelerating palatal healing

Conditions: Gingival Recession

Summary: backgroung: various agents are used to reduce post-operative complications associated with palatal donor site surgery for free gingival graft (fgg) harvesting. this study was conducted to evaluate the effects of platelet-rich fibrin (prf) on palatal wound healing.

125 patients with isolated recessions were treated. the connective tissue graft was obtained by the de-epithelialization of a free gingival graft in both groups. three different hemostatic treatments were randomized; prf with cyanoacrilate adhesive (prf group, n:42), cyanoacrilate adhesive alone (bc group, n:42) and sterile wet gauze compression (wg group, n:41). immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded for different time points.

Eligibility criteria:
inclusion criteria: * no contraindications for periodontal surgery; * full-mouth plaque score of \<10% * full-mouth bleeding score of \<15%. exclusion criteria: * previously undergone surgery for a graft harvested from the palate * presence of systemic disease or taking medication known to interfere with periodontal health * smokers * possible coagulation disorders
treatment of apap toxicity with iv and oral nac 2008-2011

Conditions: Acetaminophen Toxicity

Summary: retrospective chart review of patients who receive n-acetylcysteine for acetaminophen(apap) toxicity to assess length of oral vs. iv treatment and the effect of a clinical pharmacology and toxicology division in the management of apap ingestions.


Eligibility criteria:
inclusion criteria: * admitted to chmca between june 1, 2008 to june 30, 2011 * qualifying icd-9 diagnosis code for the following apap overdose situations: poisoning, accidental, suicide attempt, therapeutic use, assault, and undetermined (965.4, e850.4, e950.0, e935.4, e962.0, e980.0) * serum apap concentration above the possible hepatotoxic line on the rumack-matthew's nomogram if obtained \> 4 hours post ingestion * between ages 0-21 years on date of admission * acute apap ingestion exclusion criteria: * serum apap concentrations not actually documented * did not receive the oral or iv nac treatment * preexisting liver disease such as cirrhosis or hepatitis c * patient \> 21 years of age on the date of admission * chronic apap ingestion

Keywords: acetaminophen toxicity acetaminophen overdose n-acetylcysteine liver toxicity
the effects of sorafenib on molecular barrett's esophagus cancer

Conditions: Esophageal Cancer

Summary: to determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.

to characterize the effects of sorafenib on specific molecular markers in patients with barrett's esophagus and high grade intraepithelial neoplasia (hgin) or carcinoma in situ (cis).

Eligibility criteria:
inclusion criteria: * ecog performance status 0-2 * life expectancy of greater than 12 months * no prior history of esophageal surgery or endoscopic treatment of dysplasia * no prior exposure to sorafenib * patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer) * age 18 years. * patients must have adequate organ and marrow function as defined below: * hemoglobin: 8.5 g/dl * absolute neutrophil count: 1,500/l * platelets: 100,000/l (greater than 35,000/l without transfusion for less than 1 x the institutional upper limit of normal) * creatinine less than 1.5 x institutional upper limit of normal * ability to understand and the willingness to sign a written informed consent. exclusion criteria: * a patient will be withdrawn from the study if any of the following events occur while on therapy: * interruption of scheduled therapy for greater than 7 days * intolerable adverse effects which are judged by the investigator to be either physically or psychologically detrimental to the patient * patient decision to discontinue treatment * pregnancy * patient non-compliance with therapy administration * grade 3 or 4 nci-ctc toxicity attributable to sorafenib * treatment with other chemotherapeutic or investigational anti-neoplastic drugs * disease progression * hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.

Keywords: esophageal cancer
a study of aripiprazole lauroxil in subjects with schizophrenia or schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.


Eligibility criteria:
inclusion criteria: * has a diagnosis of chronic schizophrenia or schizoaffective disorder * has demonstrated ability to tolerate aripiprazole * has been on a stable antipsychotic medication regimen without any changes for at least 2 months prior to screening * has a body mass index (bmi) of 18.0 to 40.0 kg/m2, inclusive * additional criteria may apply exclusion criteria: * is pregnant, is planning to become pregnant, or is currently breastfeeding * has received aripiprazole lauroxil or im depot aripiprazole within 6 months, or other long-acting, injectable antipsychotic medication within 3 months or currently treated with clozapine * is a danger to himself/herself at screening or upon admission * has a history of or positive test result for human immunodeficiency virus (hiv), hepatitis b, or hepatitis c * has a positive urine drug screen at screening or day 1 * additional criteria may apply

Keywords: schizophrenia schizoaffective disorder aripiprazole lauroxil aripiprazole alks 9072 alkermes
induction of labor in oligohydramnios

Conditions: Cervical Ripening

Summary: when oligohydramnion - decreased amniotic fluid, is diagnosed at term pregnancies, the common practice is to induce labor. whenever the cervix is not ripened, there are several methods to ripen the cervix, two of which are: mechanical, using a double balloon catheter and pharmacological, with prostaglandins. the aim of the study is to compare those two methods of cervical ripening for patients with significant oligohydramnion at term. the study will be a prospective randomised trial.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * normal pregnancy, well dated, at term * un ripened cervix exclusion criteria: * previous cesarean section * multiple pregnancy * intra uterine growth restricted fetus
observational clinical study to plan, position and check instrument placement for spine surgery interventions

Conditions: Spinal Diseases

Summary: there is a clear need in spine surgery to place pedicle screws in the right place in the spine with good accuracy to avoid damage to important structures (spinal cord, nerve roots or vertebral arteries). the objective of the study was to investigate the accuracy of screw placement during spine surgery.


Eligibility criteria:
inclusion criteria: * subject undergoing a spine surgery with pedicle screw placement * subject 16 years of age or older * subject able to give informed consent exclusion criteria: * subject participating in a potentially confounding device or drug trial during the course of the study. * subject meeting an exclusion criteria according to national law (e.g. pregnant woman, breast feeding woman)
determination of the acute effects of aortic stenosis on coronary artery haemodynamics

Conditions: Aortic Valve Stenosis

Summary: narrowing of the main valve which controls blood leaving the heart leads to a marked increase in death. to overcome this narrowing the heart muscle thickens abnormally and contracts more vigorously. however, in doing so, blood flow patterns to the heart muscle change through mechanisms which are incompletely understood. new technology allows such heart valve blockages to be fixed using balloons and metal stents inserted through tubes placed in arteries in the leg. using sensors placed in these tubes it is possible to make detailed measurements of coronary flow and pressure, and apply new mathematical techniques to allow a better understanding of the detrimental effects that aortic stenosis has on coronary flow, before and after valve surgery.


Eligibility criteria:
inclusion criteria: * severe aortic stenosis undergoing tavi * normal coronary arteries * normal left ventricular function * no other valvular pathology exclusion criteria: * unable to consent * left ventricular impairment * left ventricular regional wall motion abnormality * other valve abnormality

Keywords: aortic stenosis coronary flow wave intensity analysis
furosemide and coarctation surgery lung complications

Conditions: Pulmonary Complication

Summary: in our study the investigators give furosemide during surgery for repair of aortic coarctation via lateral thoracotomy and evaluated lung complications in comparison to control group


Eligibility criteria:
inclusion criteria: * coarctation of aorta exclusion criteria: * heart failure, bleeding diathesis, associated cardiac congenital anomalies
technology-based intervention for reducing sexually transmitted infections and substance use during pregnancy

Conditions: Sexually Transmitted Infection; Alcohol Use Complicating the Puerperium; Alcohol Use Complicating Pregnancy, Unspecified Trimester; Drug Use

Summary: this proposed study is to test whether health check-up for expectant moms (hcem), a computer-delivered screening and brief intervention (sbi) that simultaneously targets sexually transmitted infection (sti) risk and alcohol/drug use during pregnancy, reduces antenatal and postpartum risk more than an attention, time, and information matched control condition among pregnant women seeking prenatal care.


Eligibility criteria:
inclusion criteria: * at least one unprotected vaginal (or anal) sex occasion in the past 30 days * having more than one male sex partner in the last 6 months and/or having uncertainty about current partner's monogamy. * pregnant * current alcohol/drug use risk. exclusion criteria: * unable to understand english
phase 2a clinical trial to evaluate the efficacy and safety of hl301 on radiation pneumonitis in non-small cell lung cancer patients

Conditions: Radiation Pneumonitis; Lung Cancer

Summary: the purpose of this clinical trial is to evaluate the safety when hl301 is administered to unresectable non-small cell lung cancer patients who receive chemoradiotherapy with paclitaxel and carboplatin and to search for a clinically appropriate dose by evaluating the efficacy by comparing the radiation pneumonia incidence rate with the control group.


Eligibility criteria:
inclusion criteria: * male or female, age ≥ 19 years * stage iii non-small cell lung cancer(nsclc) patient who without surgical treatment * patients scheduled for curative concurrent chemoradiotherapy * chemotherapy : paclitaxel and carboplatin * radiation therapy : imrt, total 60\~70gy * eastern cooperative oncology group(ecog) performance status of 0 to 2 at the screening visit * subject whose remaining life expectancy is more than 6 months according to the judgment of investigator * volunteer, be willing and able to provide written informed consent for the trial exclusion criteria: * subjects with pleural effusion * subjects with a weight loss of 10% or more within the last 6 months from the screening visit * subjects with a history of thoracic or neck radiotherapy or chemotherapy prior to screening visit * subjects with distant metastases * subjects with liver/renal dysfunction according to the following criteria on the screening test * total bilirubin \>1.5 mg/dl * alt or ast level is 2.0 times higher than the upper limit of normal (based on the institution) * serum creatinine \>1.5 mg/dl * subjects with serious cardiovascular disease within 3 months prior to the screening visit (ex. arrhythmia, congestive heart failure, infarction, unstable angina etc) * subjects with serious systemic infection (≥ grade 3, evaluated by ctcae v5.0) * patients with chronic or interstitial lung disease (excluding patients with chronic obstructive pulmonary disease (copd)), patients with chronic bronchitis, patients with pneumonia * subjects with thyroid dysfunction as present illness at the screening visit * subjects who administered systemic steroids within 4 weeks prior to the date of randomization (except for cases when administered to prevent hypersensitivity reaction of paclitaxel) * subjects who are hypersensitive to investigational products and standard anticancer treatments * subjects who participate in other clinical trials within 30 days prior to the screening visit and administer investigational drugs or apply clinical trial medical devices * women of childbearing age or men who do not agree to use a medically accepted method of contraception during the clinical trial * pregnant or breast-feeding * subjects who have clinical significance that is considered inappropriate for this clinical trial as judged by the investigator
multicenter study to evaluate a new robotic device for image-guided percutaneous needle placement

Conditions: Hepatic Tumor

Summary: this study evaluates the safety and performance of a new robotic device in the treatment of hepatic thermoablation in adults. the new robotic device will be used in all patients.

the device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of needle, as well as in verification of needle position during ct guided percutaneous ablation procedures. after validation of the correct positioning of the needle, the tumor ablation procedure is conducted with a device routinely used by the investigator. the acquisition of a post-interventional ct-guided image is realized to evaluate adverse events occurrence.

Eligibility criteria:
inclusion criteria: * patient is at least 18 years old, * patient for whom an ablation procedure under ct guidance in liver organ has been prescribed and consensually agreed by a multidisciplinary team of radiologists, surgeons and clinicians, * patient not taking platelet antiaggregant or having stopped taking it for 5 days and not taking anticoagulant (thrombocytes ≥ 50 000/mm3, tp \> 50%), * patient who agrees to participate in the evaluation and who has signed the inform consent, * patient covered by social security system. exclusion criteria: * patient unable to undergo general anesthesia, * patient unable to tolerate ct contrast agent * patient already participating in another clinical study * pregnant or breast-feeding woman.
study to determine the maximum range of light doses at two hpph doses with acceptable normal tissue toxicity for pdt treatment of high grade dysplasia,cis or early adenocarcinoma in barrett's esophagus

Conditions: Barrett's Esophagus; CIS; HGD

Summary: patient's with high grade dysplasia, carcinoma in situ or early adenocarcinoma in barrett's esophagus are injected with hpph and one day later are endoscopically treated with light from a laser.


Eligibility criteria:
inclusion criteria: * patient must have biopsy proven high-grade (severe)dysplasia, carcinoma-in-situ or early stage adenocarcinoma * patient may have received prior therapy; e.g.nd-yag laser, radiation therapy or chemotherapy. at least one-month must have elapsed between prior treatments and pdt * tumors (hgd/cis or early adenocarcinoma) can be primary or recurrent, stage 0 or i n0m (any) * patients must have no contraindication to endoscopy * male or female patients must be 18 years old or older. female patients must not be pregnant and must be practicing a medically acceptable form of birth control or be sterile or post-menopausal. a pregnancy test is required and must be negative. * patients must sign an informed consent according to fda guidelines and be acceptable to the rpci irb * patients must have a karnofsky status 50 or above. * patients with early invasive adenocarcinoma will be included only if they are considered poor surgical risks, have failed or refused xrt/chemo, or refused surgery. * if the patients has had cancer other than non-melanoma skin cancer, their treating physician must deem them disease-free. exclusion criteria: * patients with tumors of grade greater than t-1. * porphyria or hypersensitivity to porphyrin or porphyrin-like compounds * wbc\<4000; platelet count\<100,000; prothrombin times 1.5 times above upper normal limit. * patients with impaired renal and/or hepatic function (total serum bilirubin \> 3.0 mg/d, serum creatinine\>3 mg%, alkaline phosphatase (hepatic) or sgot\> 3 times the upper normal limit. * patients on concurrent chemotherapy or radiation therapy will be excluded as well as those having received prior treatment for the esophageal cancer within 4 weeks of enrollment.
pre-hospital notification of injured patients presenting to trauma centres in india

Conditions: Major Trauma

Summary: a prospective observational study using an interrupted time-series design to evaluate the effect of pre-hospital notification on trauma patients arriving at a trauma centre by ambulance, in india

this is a longitudinal prospective cohort study of injured patients being transported by ambulance to the major trauma centre study sites. in the pre-intervention phase, prospective data on patients will be collected on pre-hospital assessment, notification, in-hospital assessment, management and outcomes and recorded in a new tailored multi-hospital trauma registry. all injured patients arriving by ambulance and allocated to a red or yellow priority category will be eligible for inclusion. the intervention will be a pre-hospital notification application in the form of an android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient. the application will use a simple algorithm based on trauma triage principles developed by the australia-india trauma system collaboration (aitsc). the proportion of severely injured patients arriving to hospital after notification will be the primary outcome measure with a target of 70%. secondary outcomes evaluated will be availability of a trauma cubicle, presence of a trauma team on patient arrival, time to first chest x-ray and in-hospital mortality.

Eligibility criteria:
inclusion criteria: all injured patients arriving by ambulance and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. data will be collected prospectively by trained data collectors positioned in the trauma centres. retrospective inclusion will be continued for all screened patients presenting to any of the included hospitals with injury (including near-drowning) as the primary diagnosis and with at least one of the following criteria: 1. admission to hospital 2. death after triage but before admission 3. dead on arrival exclusion criteria: patients meeting screening criteria will be subsequently excluded if they meet any of the following criteria: 1. dead at scene 2. alive at triage but not admitted to hospital (discharged alive) 3. isolated poisoning 4. isolated burns 5. single digit finger or toe amputations (unless of the thumb or great toe), only

Keywords: injury injuries triage